Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

9drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: PCSK9i ×

PCSK9i

This drug is selected. Its supporting articles are shown below.

Articles mentioning PCSK9i

3 articles · page 1 of 1

4CPS-015 Pharmacist’s role in the follow-up of patients treated with PCSK9i inhibitors

ejhpharm · abstract · 2026-03-18 · 4 matching annotations

93.8%

evolocumab alirocumab PCSK9i ezetimibe bempedoic acid hypercholesterolaemia tertiary care hospital

…s with hypercholesterolaemia treated with PCSK9i (alirocumab or evolocumab).To assess the acceptance rate of the interventions.Material an…

PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial

bmjopen · abstract · 2026-03-18 · 4 matching annotations

96.6%

PCSK9i Proprotein convertase subtilisin/kexin type 9 inhibitors acute coronary syndrome (ACS)NCT06791031 Biomedical Research Ethics Committee of West China Hospital of Sichuan University ACS

…randomised 1:1 to an early intensified lipid-lowering strategy (PCSK9i added to moderate-intensity statin) or guideline-directed medic…

PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs

openhrt · abstract · 2025-08-21 · 1 matching annotations

83.8%

inclisiran evolocumab alirocumab bococizumab tafolecimab PCSK9i atherosclerotic cardiovascular disease Familial hypercholesterolaemia (FH)

… including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (…